Date: 2013-08-06
Type of information:
Compound: antibody half-life extension technology NHance™
Company: arGEN-X (The Netherlands - Belgium) undisclosed partner
Therapeutic area:
Type agreement: licensing
Action mechanism: NHance™is an arGEN-X proprietary technology capable of increasing the half life of a therapeutic antibody in the human systemic circulation. NHance™ achieves this through 2 specific mutations in the antibody Fc region (at His433 and Asn434), resulting in an improved affinity of antibody binding to the neonatal Fc receptor at acidic pH. This receptor is responsible for recycling the antibody within the human body. Enhanced antibody serum levels resulting from prolonged half-life may lead to a higher therapeutic effect, lower material requirements for the same therapeutic effect, and/or reduced dosing frequency. The technology may also further enhance antibody transport across mucosal barriers, enabling alternative routes of antibody product administration.
Disease:
Details: * On August 6, 2013, arGEN-X, a clinical stage biopharmaceutical company specialized in the creation and development of highly differentiated human antibody therapeutics, has announced the signing of its second non-exclusive license agreement for its antibody half-life extension technology, NHance™. Both licenses granted to date are with companies dedicated to developing and commercializing antibody-based therapeutics with clear clinical benefits. Under the terms of these agreements, arGEN-X receives upfront technology access and annual license maintenance fees, in addition to clinical milestone payments and tiered royalties on product sales. No further details are being disclosed.
Financial terms:
Latest news:
